Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions.
Colby's lead drugs have unique mechanisms of action and target specific pathways. The Company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs.
Colby CEO, David Zarling PhD MBA was previously Executive Vice President and then CEO of PGC, a genomics/oncology drug target bio-validation service-based spin-out from Pharma Drug at SRI.
Chief Medical Officer, Minesh Mehta MD is also currently at UWCCC and was Chief Clinical Advisor for TomoTherapy, which successfully completed a $200M IPO (NASDAQ:TOMO) in 2007.
Chief Scientific Officer, Hirak Basu PhD is also currently at UWCCC and was former Associate Director of Oncology Drug R&D at SLIL Biomedical and has developed two oncology drugs which are in clinical trials.
VP, Anne Vallerga PhD was former IRB Manager at Stanford University Medical School.
Colby's Scientific Advisory Board (SAB)
Co-Chairman, George Wilding MD, is also Director UWCCC, Madison, Wisconsin.
Colby's SAB Co-Chairman, Richard Zare PhD, is also Chairman, Stanford University Department of Chemistry, Stanford, CA. The Colby SAB membership includes internationally recognized oncology expert, Hasan Mukhtar PhD, who is at UWCCC.
